Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.
The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
According to researcher Anne Robertson, the bladder is not considered a particularly glamorous organ, despite hosting many of ...
The bladder cancer treatment landscape is rapidly evolving, particularly for patients who don’t respond to bacillus ...
Patients with initially low- or intermediate-risk primary tumors will often have a high-risk recurrence before progressing to more advanced disease, whereas primary high-risk tumors typically show ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback